EVIDENCE PROFILE / PUBLISHED
Thymosin alpha-1
Thymosin alpha-1 is a 28-amino-acid peptide also known as thymalfasin; branded approvals reported outside North America do not validate an unspecified material. A 2025 multicentre double-blind phase 3 trial in 1,106 adults with sepsis found no clear reduction in 28-day all-cause mortality. Older, smaller studies in other diseases are not interchangeable.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. It is studied as an immune-modulating peptide across infection, critical illness, cancer adjunct, and immune-function settings.
Identity
Thymosin alpha-1 is a 28-amino-acid peptide also known as thymalfasin; branded approvals reported outside North America do not validate an unspecified material.
Biological mechanism or research interest
It is studied as an immune-modulating peptide across infection, critical illness, cancer adjunct, and immune-function settings.
Verified approved human uses
No Canadian or U.S. approved use was verified in the reviewed sources. This does not claim worldwide absence.
Investigational human evidence
A 2025 multicentre double-blind phase 3 trial in 1,106 adults with sepsis found no clear reduction in 28-day all-cause mortality. Older, smaller studies in other diseases are not interchangeable.
Popular claims versus demonstrated findings
Immune boosting, infection treatment, cancer benefit, and broad resilience claims exceed the mixed, disease-specific evidence.
Human versus animal or cell evidence
Immune-marker mechanisms do not prove patient-important outcomes, as the large sepsis trial illustrates.
Limitations and known risks
FDA identifies inadequate safety information for proposed compounded use, including potential immunogenicity and peptide-characterization complexity.
